Overview

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Phase II, two arms, parallel, non comparative study with crizotinib in patients with ROS 1 translocation or MET amplification or MET exon 14 mutation
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione Ricerca Traslazionale
Treatments:
Crizotinib